- Author: Jerry L Halverson, MD; Chief Editor: David Bienenfeld, MD more...
Major depressive disorder has significant potential morbidity and mortality, contributing to suicide (see the image below), incidence and adverse outcomes of medical illness, disruption in interpersonal relationships, substance abuse, and lost work time. With appropriate treatment, 70-80% of individuals with major depressive disorder can achieve a significant reduction in symptoms.
Signs and symptoms
Most patients with major depressive disorder present with a normal appearance. In patients with more severe symptoms, a decline in grooming and hygiene may be observed, as well as a change in weight. Patients may also show the following:
Flattening or loss of reactivity in the patient's affect (ie, emotional expression)
Psychomotor agitation or restlessness
Major depressive disorder
Among the criteria for a major depressive disorder, at least 5 of the following symptoms have to have been present during the same 2-week period (and at least 1 of the symptoms must be diminished interest/pleasure or depressed mood) :
Depressed mood: For children and adolescents, this can also be an irritable mood
Diminished interest or loss of pleasure in almost all activities (anhedonia)
Significant weight change or appetite disturbance: For children, this can be failure to achieve expected weight gain
Sleep disturbance (insomnia or hypersomnia)
Psychomotor agitation or retardation
Fatigue or loss of energy
Feelings of worthlessness
Diminished ability to think or concentrate; indecisiveness
Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan for committing suicide
See Clinical Presentation for more detail.
Self-report screening instruments for depression include the following:
Patient Health Questionnaire-9 (PHQ-9): A 9-item depression scale; each item is scored from 0-3, providing a 0-27 severity score.
Beck Depression Inventory (BDI) or the Beck Depression Inventory-II (BDI-II): 21-question symptom-rating scales providing a 0-63 severity score.
BDI for primary care: A 7-question scale adapted from the BDI.
Zung Self-Rating Depression Scale: A 20-item survey.
Center for Epidemiologic Studies-Depression Scale (CES-D): A 20-item instrument that allows patients to evaluate their feelings, behavior, and outlook from the previous week.
In contrast to the above self-report scales, the Hamilton Depression Rating Scale (HDRS) is performed by a trained professional, not the patient. The HDRS has 17 or 21 items, scored from 0-2 or 0-4; a total score of 0-7 is considered normal, while scores of 20 or higher indicate moderately severe depression.
The Geriatric Depression Scale (GDS), although developed for older adults, has also been validated in younger adults. The GDS contains 30 items; a short-form GDS has 15 items.
No diagnostic laboratory tests are available to diagnose major depressive disorder, but focused laboratory studies may be useful to exclude potential medical illnesses that may present as major depressive disorder.
See Workup for more detail.
In all patient populations, the combination of medication and psychotherapy generally provides the quickest and most sustained response.[2, 3]
Drugs used for treatment of depression include the following:
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin/norepinephrine reuptake inhibitors (SNRIs)
Tricyclic antidepressants (TCAs)
Monoamine oxidase inhibitors (MAOIs)
St. John's wort ( Hypericum perforatum)
Evidence-based psychotherapeutic treatments for adults with major depressive disorder include the following:
Interpersonal psychotherapy (IPT)
Cognitive-behavioral therapy (CBT)
Problem-solving therapy (PST)
Behavioral activation (BA)/contingency management
Evidence-based psychotherapeutic treatments for children and adolescents with major depressive disorder include the following:
Interpersonal psychotherapy (IPT)
Cognitive-behavioral therapy (CBT)
Behavior therapy (BT)
Many of these treatments incorporate a parent/family component when working with children or adolescents.
In mild cases, psychosocial interventions are often recommended as first-line treatments. The American Psychiatric Association (APA) guideline supports this approach but notes that combining psychotherapy with antidepressant medication may be more appropriate for patients with moderate to severe major depressive disorder.
Electroconvulsive therapy (ECT) is a highly effective treatment for depression. The indications for ECT include the following:
Need for a rapid antidepressant response
Failure of drug therapies
History of good response to ECT
High risk of suicide
High risk of medical morbidity and mortality
Transcranial magnetic stimulation (TMS) is approved by the FDA for treatment-resistant major depression.
Vagus nerve stimulation (VNS) has been approved by the FDA for use in adult patients who have failed to respond to at least 4 adequate medication and/or ECT treatment regimens. The stimulation device requires surgical implantation.
As many as two thirds of people with depression do not realize that they have a treatable illness and therefore do not seek professional help. In addition, persistent ignorance and misperceptions of the disease by the public, including many health providers, as a personal weakness or failing that can be willed or wished away leads to painful stigmatization and avoidance of the diagnosis by many of those affected.
In the primary care setting, where many of these patients first seek treatment, the presenting complaints often can be somatic, such as fatigue, headache, abdominal distress, or sleep problems. (See Presentation.)
The American Psychiatric Association’s Diagnostic Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies the depressive disorders as disruptive mood dysregulation disorder, major depressive disorder (including major depressive episode), persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, and depressive disorder due to another medical condition. In addition, depressive disorders may be further categorized by specifiers that include peripartum onset, seasonal pattern, melancholic features, mood-congruent or mood-incongruent psychotic features, anxious distress, and catatonia. The common feature of the depressive disorders is the presence of sad, empty, or irritable mood, accompanied by somatic and cognitive changes that significantly affect the individual’s capacity to function. What differs among them are issues of duration, timing, or presumed etiology.
The differential diagnosis for depression includes other psychiatric disorders, CNS diseases, endocrine disorders, drug-related conditions, infectious and inflammatory diseases, and sleep-related disorders. (See DDx.)
Depression screening tests can be used to screen for depression and bipolar disorder. The most widely used is the Patient Health Questionnaire-9 (PHQ-9). It is important to understand that the results obtained from the use of any depression rating scales are imperfect in any population, especially the geriatric population. (See Workup.)
Many effective treatments are available for major depressive disorder, including psychotherapy (eg, cognitive-behavioral therapy, interpersonal psychotherapy, behavior therapy), used either alone or in combination with medication. However, the combined approach provides some patients with the quickest and most sustained response. Uncomplicated depression that is not severe typically responds equally well to psychotherapy or an antidepressant. (See Treatment.)
There is evidence to support the use of all antidepressants approved by the FDA for use in major depression, although predicting what an individual patient’s response to a particular agent will be is difficult. Assuming adherence to the treatment regimen and lack of drug or disease-state interactions, treatment for 2-12 weeks at a therapeutic-dose level is usually needed to achieve a clinical response. The choice of medication should be guided by anticipated safety and tolerability, physician familiarity, and personal and family history of previous treatments. (See Medications.)
This article focuses on major depressive disorder in adults. For information on depression in children and adolescents, see the Medscape Reference article Pediatric Depression. For information on depression in bipolar disorder, see Bipolar Affective Disorder.
The underlying pathophysiology of major depressive disorder has not been clearly defined. Current evidence points to a complex interaction between neurotransmitter availability and receptor regulation and sensitivity underlying the affective symptoms.
Clinical and preclinical trials suggest a disturbance in central nervous system serotonin (5-HT) activity as an important factor. Other neurotransmitters implicated include norepinephrine (NE), dopamine (DA), glutamate, and brain-derived neurotrophic factor (BDNF). However, drugs that produce only an acute rise in neurotransmitter availability, such as cocaine or amphetamines, do not have the efficacy over time that antidepressants do.
The role of CNS 5-HT activity in the pathophysiology of major depressive disorder is suggested by the therapeutic efficacy of selective serotonin reuptake inhibitors (SSRIs). In addition, studies have shown that an acute, transient relapse of depressive symptoms can be produced in research subjects in remission using tryptophan depletion, which causes a temporary reduction in CNS 5-HT levels. However, the effect of SSRIs on 5HT reuptake is immediate, but the antidepressant effect requires exposure of several weeks' duration. Also, some antidepressants have no effect on 5HT (eg, desipramine), and the antidepressant tianeptine enhances 5HT uptake. All this, together with preclinical research findings, implies a role for neuronal receptor regulation, intracellular signaling, and gene expression over time, in addition to enhanced neurotransmitter availability.
Seasonal affective disorder is a form of major depressive disorder that typically arises during the fall and winter and resolves during the spring and summer. Studies suggest that seasonal affective disorder is also mediated by alterations in CNS levels of 5-HT and appears to be triggered by alterations in circadian rhythm and sunlight exposure.
Vascular lesions may contribute to depression by disrupting the neural networks involved in emotion regulation—in particular, frontostriatal pathways that link the dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate, and dorsal cingulate. Other components of limbic circuitry, in particular the hippocampus and amygdala, have been implicated in depression.
Functional neuroimaging studies support the hypothesis that the depressed state is associated with decreased metabolic activity in neocortical structures and increased metabolic activity in limbic structures. Serotonergic neurons implicated in affective disorders are found in the dorsal raphe nucleus, the limbic system, and the left prefrontal cortex.
A meta-analysis comparing brain structures in patients with major depression, in healthy controls, and in patients with bipolar disorder demonstrated associations between depression and increased lateral ventricle size, larger cerebrospinal fluid volume, and smaller volumes of the basal ganglia, thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus. Patients experiencing a depressive episode had smaller hippocampal volume than those in remission.
In one study, positron emission tomographic (PET) images showed abnormally diminished activity in an area of the prefrontal cortex in patients with unipolar depression and bipolar depression. This region is related to emotional response and has widespread connections with other areas of the brain, including the areas that appear to be responsible for the regulation of DA, noradrenaline (locus ceruleus), and 5-HT (raphe nuclei).
Both functional and structural abnormalities were found in the same brain region during a major depressive episode. Sacher et al found increases in glucose metabolism in the right subgenual and pregenual anterior cingulate cortices and decreased gray matter volumes in the amygdala, dorsal frontomedian cortex, and right paracingulate cortex.
An integrative model of late-onset depression posits that age-related brain changes and disease-related changes (eg, cerebrovascular disease), coupled with physiologic vulnerabilities (eg, genetic risk factors, personal history of depression) and psychosocial adversity, lead to disruptions in the functional circuitry of emotion regulation—namely, hypometabolism of cortical structures and hypermetabolism of limbic structures.
Endocrine changes in depression are evident across the life span, but some are unique to aging. Women with a previous history of depression are at higher risk of developing depression during menopause, although estrogen replacement does not relieve depression; low testosterone levels have been associated with depression in older men.
The specific cause of major depressive disorder is not known. As with most psychiatric disorders, major depressive disorder appears to be a multifactorial and heterogeneous group of disorders involving both genetic and environmental factors.
Evidence from family and twin studies indicates that with depression that develops in early childhood, the transmission from parents to children appears to be related more to psychosocial influences than to genetics. Adolescent-onset and adult-onset depression, while more heritable than prepubertal depression, likewise reflect an interaction between genes and environmental stressors.
Genetic factors play an important role in the development of major depression. Evidence from twin studies suggests that major depression has a concordance of 40-50%. First-degree relatives of depressed individuals are about 3 times as likely to develop depression as the general population; however, depression can occur in people without family histories of depression, as well.
Two susceptibility loci have been identified in which no specific gene of interest has been definitively identified. The MDD1 locus is located at 12q22-q23.2 and is most strongly linked to major depression in males. The MDD2 locus is located at 15q25.2-q26.2 and has been associated with early onset or recurrent episodes of depression.
Although multiple genes are likely to influence the susceptibility to depression, those involved in the serotonin system are a focus of investigation, especially because many antidepressant medications work by influencing serotonin. The SLC6A4 gene, which is located at 17q11.2, encodes a serotonin transporter (also known as 5-hydroxytryptamine transporter) that is responsible for actively clearing serotonin from the synaptic space.
A polymorphism in the promoter region of the SLC6A4 gene consists of a 44bp insertion or deletion involving repeat elements. These polymorphisms are referred to as either a long allele or a short allele. Caspi et al found that persons who were homozygous or heterozygous for the short allele had more depressive symptoms and suicidality in association with stressful life events than those patients who were homozygous for the long allele.
Other studies also suggest that genes controlling either the production or utilization of serotonin play an important role in the pathogenesis of depression. The TPH2 gene encodes tryptophan hydroxylase, which is the rate-limiting enzyme in the synthesis of serotonin. An in vitro study of a TPH2 polymorphism, R441H, found an approximately 80% loss in serotonin production.
The clinical significance of this polymorphism remains uncertain, however. Zhang et al found that the allele was more common in a cohort of patients with major depression than in a control population, but a later study by Garriock et al did not find any patients with the R441H mutation in a cohort with major depression, a control group, or a group with bipolar disorder.
The HTR3A and HTR3B regions, which encode serotonin receptors and are located at chromosome 11q23.2, are also known to be associated with major depression in both European and Japanese populations. Yamada e al surveyed 29 polymorphisms located within the HTR3A and HTR3B genes and found a single-nucleotide polymorphism that was associated with depression in females.
A study of genes in the hypothalamic-pituitary-adrenal axis found that in patients with major depression, homozygosity for the T allele in the FKBP5 gene was associated with a quicker response to antidepressants than heterozygosity or homozygosity for the C allele in that location. However, homozygosity for the T allele was also associated with an increased recurrence of depressive episodes.
Studies such as those reported by Akiskal and Weller and Weissman et al suggest a genetic component in the etiology of depressive disorders. Individuals with a family history of affective disorders, panic disorder, or alcohol dependence carry a higher risk for major depressive disorder.
Children and adolescents
Nobile et al found that human platelet 5-HT uptake is differentially influenced in children and adolescents with and without depression by a common genetic variant of the promoter region of the serotonin transporter gene (5-HTTLPR). Depressed persons had a lower rate of serotonin uptake and a lower serotonin dissociation constant
Birmaher et al found that before the onset of affective illness, children who were at high risk for depression, on the basis of family history, had the same pattern of neuroendocrine response to infusion of a serotonergic precursor (5-hydroxy-L-tryptophan) challenge as did children with major depression. Compared with low-risk children, high-risk children and depressed children secreted significantly less cortisol and, in girls, more prolactin. These findings could constitute the identification of a trait marker for depression in children.
Some evidence suggests that late-onset depression (after age 60 years) is an etiologically and clinically distinct syndrome and that genetic factors likely play less of a role in late-onset depression than in early-onset depression. A family history of depression is less common among patients with late-onset depression than in younger adults with depression. However, although findings have been inconsistent, certain genetic markers have been found to be associated with late-onset depression. Such markers include polymorphisms of apolipoprotein E, BDNF, and 5-HT transporter genes. Interestingly, these markers have also been associated with cognitive impairment, hippocampal volume, and antidepressant response, respectively.
Genetic influences on antidepressant drug response
Genetics also play a significant part in the response to pharmacologic treatment of major depression. A study of the drug transporter gene ABCB1 (which encodes a transporter glycoprotein and functions as an active efflux pump for a number of drugs across the blood-brain barrier) found an association between 2 single-nucleotide polymorphisms and achievement of remission with citalopram, paroxetine, amitriptyline, and venlafaxine. Also, in a mouse model lacking the gene homologous to the human ABCB1 gene, the mice had significantly higher concentrations of citalopram, venlafaxine, or desvenlafaxine after 11 days of subcutaneous administration of the drugs, despite drug plasma concentrations that were identical to those in mice lacking this mutation.
Approximately 40% of patients who are treated with a selective serotonin reuptake inhibitor (SSRI) will either discontinue treatment or switch medications because of an adverse effect of the medication. In one study, an increased risk for sexual dysfunction from SSRIs was found to be associated with alleles in the 5HT2A and GHB3 genes.
A study of response to treatment with citalopram identified a significant association between treatment outcome and a marker in HTR2A, which is located at chromosome 13q14.2 and encodes the serotonin 2A receptor. The A allele (a single-nucleotide polymorphism in an intron of this gene) reduced the likelihood of nonresponse to citalopram in whites but not in the African-American population. An AA genotype resulted in a 16-18% reduction in absolute risk of being a nonresponder.
Although major depressive disorder can arise without any precipitating stressors, stress and interpersonal losses certainly increase risk. For example, loss of a parent before the age of 10 years increases the risk of later depression. Cognitive-behavioral models of depression posit that negative cognitions and underlying all-or-nothing schemata contribute to and perpetuate depressed mood.
Chronic pain, medical illness, and psychosocial stress can also play a role in major depressive disorder. Older adults may find medical illness psychologically distressing, and these illnesses may lead to increased disability, decreased independence, and disruption of social networks. Chronic aversive symptoms such as pain associated with chronic medical illness may disrupt sleep and other biorhythms leading to depression.
Other psychosocial risk factors for depression in late life include the following :
Impaired social supports
Negative life events
Cognitive-behavioral models of depression suggest that the presence of negative life events in addition to one’s perception of or reaction to those events may impact the development and maintenance of depressive symptoms. Cognitive models of depression posit that negative cognitions and underlying all-or-nothing schemata contribute to and perpetuate depressed mood. More specifically, cognitive vulnerability-stress models suggest that, in the face of negative life events, individuals who have a tendency to make negative attributions about the causes of those events, about themselves, and about future consequences (in line with the hopelessness theory of depression) may be more likely to develop depression. This has been suggested as potentially contributing to gender differences in rates of depression following puberty (e.g., Hyde, Mezulis, and Abramson ). Behavioral models suggest that depression may result from deficits in response-contingent positive reinforcement andinadequate social skills or reliance upon escape and avoidance behaviors, such that avoidance behaviors in response to negative life events and corresponding negative emotions may lead to worsened depression.
In addition, neurochemical hypotheses point to the deleterious effects of cortisol and other stress-related substances on the neuronal substrate of mood in the CNS.
Exposure to certain pharmacologic agents increases the risk of depression, such as reserpine, beta-blockers, and steroids such as cortisol. Abused substances can also increase risk of major depressive disorder, such as cocaine, amphetamine, narcotics, and alcohol. With agents of abuse, however, it is unclear whether depression is a consequence or facilitator.
Researchers are currently investigating the relationship between genetic vulnerability, environmental stressors, and brain structural abnormalities in the development of depression. In an MRI genetic study, Frodl et al found that patients with major depression who carried the S allele of 5-HTTLPR and had a history of childhood emotional neglect had smaller hippocampal volumes than patients who had only one of those factors. They concluded that structural hippocampal brain changes resulting from stress may be part of the risk for developing depression and that these changes are more pronounced in individuals with the S-allele.
Conflicting evidence exists regarding the interaction between the functional serotonin transporter promoter (5-HTTLPR) and stress in the development of depression. A 2011 meta-analysis suggested that 5-HTTLPR moderates the relationship between stress and depression. Earlier, smaller meta-analyses had concluded that the evidence did not support the presence of the interaction.
Neuroendocrine abnormalities and neurodegenerative diseases
Possible abnormalities of the neurotransmitter systems remain under investigation. Compared with control subjects, depressed prepubertal children had lower cortisol secretion during the first 4 hours of sleep, according to De Bellis et al. Nocturnal secretion of adrenocorticotropin, growth hormone, and prolactin did not differ between the 2 groups.
Potential biological risk factors have been identified for depression in the elderly. Neurodegenerative diseases (especially Alzheimerdisease and Parkinsondisease), stroke, multiple sclerosis, seizure disorders, cancer, macular degeneration, and chronic pain have been associated with higher rates of depression.
The parent-child relation model conceptualizes depression as the result of poor parent-child interaction. Adults with depression report low paternal involvement and high maternal overprotection during early childhood. Troubled relationships with parents, siblings, and peers are common in children and adolescents with affective illness.
Affective illness in a parent may be a factor in child abuse and/or neglect that promotes affective illness in the child. Childhood abuse and neglect, as well as a cumulative load of stressors over a lifetime, have been associated with both early-adult and late-onset depression.
Hammen et al reported a significant temporal association between depression diagnoses in mother and child. They found that children with substantial stress exposure who also had symptomatic mothers were significantly more depressed than children who were exposed to comparable levels of stress only.
Mothers’ remission from depression, regardless of timing, has a consistently favorable influence on their children. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Child study, all children whose mothers experienced remission from depression showed improvement in mood and behavior in the following year; children whose mothers recovered from depression within the first 3 months of treatment showed not only improved mood and behavior but significant improvement in functioning, as well.
The vascular depression hypothesis posits that cerebrovascular disease may cause or contribute to late-life depression. Various lines of evidence support this hypothesis, including the following :
Higher incidence of depression following a left-sided stroke
Higher prevalence of ischemic white-matter changes in older adults with depression than those without
Bidirectional association between depression and coronary artery disease and depression and diabetes
United States statistics
The lifetime incidence of major depressive disorder in the United States is 20% in women and 12% in men. The point prevalence is as high as 10% in patients observed in a medical setting. Klerman and Gershon et al reported a progressive increase in the incidence of major depression over the last 70 years, with high rates of affective disorders among relatives and a younger age of onset in successive cohorts.
In 2010, the Centers for Disease Control and Prevention (CDC) released a report estimating the prevalence of current depression in adults from 2006-2008. Of 235,067 adults, 9% met the criteria for current depression, including 3.4% who met the criteria for major depression.
Internationally reported adult prevalence rates of depression generally mirror those of the United States, and estimates of 1-month prevalence of depression in community-dwelling elderly are relatively consistent (eg, England, 2.9%; The Netherlands, 2.0%; Sweden, 5.6%; Nigeria, 1.6%). However, sparse data are available on the international incidence of major depression in children and adolescents.
Helgason examined the entire Icelandic birth cohort of 1895-97 with periodic follow-up until cohort individuals reached age 74-76 years. The lifetime estimates of risk for any affective disorder were 14.8% for females and 9.8% for males. The WorldHealthOrganization(WHO) collaborative study on the assessment of depressive disorders found considerable similarity in depressive symptomatology across cultures in Canada, Iran, Japan, and Switzerland.
The Stirling County Study, which began shortly after World War II, offered a 40-year perspective of the prevalence and incidence of psychiatric disorders in an adult population in Atlantic Canada, in which the overall prevalence of depression remained stable at 5% across 3 separate samples in 1952, 1970, and 1992. In the 2000 sample, however, the prevalence had shifted from older to younger persons, and the female-to-male ratio had increased.
Copeland et al found widely ranging prevalences for depression in elderly persons in 9 European populations. The prevalence for females was higher than that for males, and there was no constant association between prevalence and age. Meta-analysis revealed an overall prevalence of 12.3% and frequencies of 14.1% for females and 8.6% for males.
Children and adolescents
The incidence of depression was 0.9% in preschool-aged children, 1.9% in school-aged children, and 4.7% in adolescents in a study by Kashani and Sherman. In another study, more than 22% of female high school students and more than 11% of male high school students reported 1 current or lifetime episode of unipolar depression. The percentage of male students with 2 or more episodes of unipolar depression was 4.9%; it was 1.6% in female students.
Garrison et al reported a 1-year incidence of major depression of 3.3% in adolescents aged 11-16 years. Their epidemiologic study was conducted between 1987 and 1989 in a single school district in the southeastern United States.
In prepubertal children, boys and girls are affected equally. Hankin et al found that the most critical time for sex differences in depression to emerge is from age 15-18 years. During this period, the increase in overall rates of depression and onset of new cases of depression peak.
Hispanic youths in Los Angeles county (aged 12-17 years) reported more symptoms of depression, independent of socioeconomic status, when compared with white, black, or Asian American adolescents, using the Children's Depression Inventory (CDI). This study also found significant effects of social class on depression. As income decreased, the average prevalence of depression increased.
Although rates of depression in women and men are highest in those aged 25-44 years, the incidence of clinically significant depressive symptoms increases with advancing age, especially when associated with medical illness or institutionalization. However, the depression might not meet criteria for major depression because of somewhat atypical features of depression in elderly persons. For instance, there is a higher prevalence of dysthymic disorder in aging and medically ill populations.
Major depressive disorder has significant potential morbidity and mortality, contributing as it does to suicide, incidence and adverse outcomes of medical illness, disruption in interpersonal relationships, substance abuse, and lost work time. With appropriate treatment, 70-80% of individuals with major depressive disorder can achieve a significant reduction in symptoms, although as many as 50% of patients may not respond to the initial treatment trial.
Twenty percent of individuals with major depressive disorder untreated at 1 year will continue to meet criteria for the diagnosis, whereas an additional 40% will have a partial remission. Pretreatment irritability and psychotic symptoms may be associated with poorer outcomes. Partial remission and/or a history of prior chronic major depressive episodes are risk factors for recurrent episodes and treatment resistance.
A study of first-episode psychotic depression by Tohen et al found that most patients achieved syndromal remission (86%) and recovery (84%); however, only 35% recovered functionally. Earlier syndromal recovery was associated with subacute onset, lower initial depression scores, and lack of mood-incongruent psychotic features. Within 2 years, almost half the patients experienced new episodes. In 41% of patients, the diagnosis was changed, usually to bipolar or schizoaffective disorders.
Recurrence of early depression
According to the AmericanAcademyofChildandAdolescentPsychiatry(AACAP) practice parameters for depressive disorders in childhood and adolescence, a history of a previous depressive episode, subsyndromal symptoms of depression, dysthymia, and anxiety disorders increase the risk for future depression. In a study of an epidemiologic sample of 776 adolescents by Pine and associates, symptoms of majordepressioninadolescencestrongly predicted episodes of major depression in adulthood.
The prognosis for patients with late-onset depression is felt to be poorer than that for younger patients, and it appears to be dependent on physical disability or illness and lack of social support. Of particular importance is the increasing risk of death by suicide, particularly among elderly men. The length of a depressive episode in the aging population is approximately 18 months, whereas in people 20–55 years of age, the length of an episode is 18 to 24 weeks.
In older patients, depression is frequently comorbid with chronic medical conditions and can lead to worsening medical outcomes, including mortality. For example, coronary artery disease is a risk factor for the development of depression, and depression is an independent risk factor for the development of coronary disease. Patients with both conditions are more likely to die than those with coronary artery disease alone. Both behavioral and physiologic explanations are likely for these associations.
Millard suggested the "rule of thirds" concerning the prognosis of late-onset depression, which states that regardless of treatment, approximately one third of patients will manifest remission, another one third will remain symptomatic in the same condition, and the remaining one third will worsen. In fact, research has shown that approximately 60% of patients with late-onset depression will have at least 1 recurrence, and up to 40% of these patients will have chronic or continuously recurrent depression.
Late-onset depression has been reported to double the risk of developing mildcognitiveimpairment and the likelihood that the mild impairment will develop into dementia. The Diabetes and Aging Study showed that when depression is comorbid with type 2 diabetes, it increases the risk of all-cause dementia by about 2-fold compared with diabetes alone. A 40-month study of 2977 middle-aged and older adults with long-standing type 2 diabetes found depression at baseline to be associated with accelerated cognitive decline.[65, 66]
Compared with participants without a depression history, those with late-life depression reportedly have increased all-cause dementia risk; however, early-life depression had no association with dementia risk. Treating depression has been suggested to possibly stunt progression to mild cognitive impairment and then to dementia, although there has been little evaluation of this hypothesis to date.
Depression plays a role in more than one half of all suicide attempts, whereas the lifetime risk of suicide among patients with untreated depressive disorder is nearly 20%. According to Centers for Disease Control and Prevention (CDC) data, suicide was the 10th leading cause of death in the United States in 2009, accounting for 36,909 deaths; it was the second leading cause of death in people 25-34 years of age, the third leading cause in people aged 10-24 years, and the fourth leading cause at ages 35-54.
However, despite these data and the fact that depression is more often diagnosed in women, the highest suicide rate is in men older than 75 years (see the graph below); more men than women die from suicide by a factor of 4.5:1. White men complete more than 78% of all suicides, and 56% of suicide deaths in males involve firearms. Poisoning is the predominant method among females. Attempted suicide is more frequent in women.
In addition to older age and male sex, risk factors for suicide include the following[70, 71] :
Diagnosis of major depression
Previous history of suicide attempts
Depressive symptoms with agitation or distress
Burden of medical disease and the presence of a current serious medical condition (although this risk may be mediated by a diagnosis of depression)
Recent stressful life events, especially family discord
Lack of social support
Being widowed or divorced
The presence of a gun in the home
Unexplained weight loss
High levels of anxiety
Lack of a reason not to commit suicide
Presence of a specific plan that can be carried out
Rehearsal of the plan
The relationship between use of antidepressants and risk of suicide varies with patient age. Treatment with antidepressants has been associated with increased suicidality in children, adolescents, and young adults 18 to 24 years of age. There is no evidence of increased risk for adults older than 24 years of age; for adults 65 years of age or older, the risk is actually decreased.
Suicide rates among Native Americans and Alaskan Natives between ages 15 and 34 years are almost twice the national average for this age range. Hispanic females make significantly more suicide attempts than their male or non-Hispanic counterparts.
In one study, there were strong correlations of suicide rates with indicators of access to health care in the United States. Multivariate analysis of state-by-state statistics showed that the state rate of federal aid for mental health was the strongest indicator, followed by the rate of uninsured persons and population density of psychiatrists and physicians and by population density. These researchers concluded that the findings support the view that clinical intervention is a crucial element in the prevention of suicide.
In 2005, 1.4% of all deaths worldwide were attributed to suicide. The actual number is unknown, as underreporting is predictably significant in many regions of the world. Suicide is estimated to be the eighth leading cause of death in all age ranges. In Eastern Europe, 10 countries report more than 27 suicides per 100,000 persons. Latin America and Muslim countries report the lowest rates, with fewer than 6.5 cases per 100,000 persons. Suicide rates increased from 1955-2009 in most countries but have decreased from 1990-2009.
Education plays an important role in the successful treatment of major depressive disorder. Over the long term, patients may also become aware of signs of relapse and may seek treatment early. Patients should be aware of the rationale behind the choice of treatment, potential adverse effects, and expected results. The involvement of the patient in the treatment plan can enhance medication compliance and referral to counseling.
Family members also need education about the nature of depression and may benefit from supportive interactions. Engaging family can be a critical component of a treatment plan, especially for pediatric and late-onset depression. Family members are helpful informants, can ensure medication compliance, and can encourage patients to change behaviors that perpetuate depression (eg, inactivity).
The following Web sites are valuable resources for patient and family education:
National Institute of Mental Health: Depression
Helpful Web sites specifically for late-onset depression include the following:
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004 Jul. 61(7):714-9. [Medline].
Ishak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, et al. The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry. 2011 Dec. 19(6):277-89. [Medline].
David-Ferdon C, Kaslow NJ. Evidence-based psychosocial treatments for child and adolescent depression. J Clin Child Adolesc Psychol. 2008 Jan. 37(1):62-104. [Medline].
APA. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd edition). Accessed May 3, 2011. American Psychiatric Association. [Full Text].
Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007 Mar. 64(3):327-37. [Medline].
Alexopoulos GS. Depression in the elderly. Lancet. 2005 Jun 4-10. 365(9475):1961-70. [Medline].
Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999 May. 156(5):675-82. [Medline].
Kempton MJ, Salvador Z, Munafò MR, Geddes JR, Simmons A, Frangou S, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry. 2011 Jul. 68(7):675-90. [Medline].
Sacher J, Neumann J, Fünfstück T, Soliman A, Villringer A, Schroeter ML. Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord. 2011 Sep 2. [Medline].
Tsuang MT, Faraone SV. The genetics of mood disorders. Baltimore, MD: Johns Hopkins University Press, 1990.
Holmans P, Zubenko GS, Crowe RR, DePaulo JR Jr, Scheftner WA, Weissman MM, et al. Genomewide significant linkage to recurrent, early-onset major depressive disorder on chromosome 15q. Am J Hum Genet. 2004 Jun. 74(6):1154-67. [Medline]. [Full Text].
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 Jul 18. 301(5631):386-9. [Medline].
Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005 Jan 6. 45(1):11-6. [Medline].
Garriock HA, Allen JJ, Delgado P, Nahaz Z, Kling MA, Carpenter L, et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry. 2005 Nov. 10(11):976-7. [Medline].
Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, et al. Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry. 2006 Jul 15. 60(2):192-201. [Medline].
Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004 Dec. 36(12):1319-25. [Medline].
Akiskal HS, Weller ES. Mood disorders and suicide in children and adolescents. In: Kaplan HI, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. 5th ed. Lippincott Williams & Wilkins; 1989. Vol 2:
Weissman MM, Leckman JF, Merikangas KR, Gammon GD, Prusoff BA. Depression and anxiety disorders in parents and children. Results from the Yale family study. Arch Gen Psychiatry. 1984 Sep. 41(9):845-52. [Medline].
Nobile M, Begni B, Giorda R, Frigerio A, Marino C, Molteni M, et al. Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999 Nov. 38(11):1396-402. [Medline].
Birmaher B, Kaufman J, Brent DA, Dahl RE, Perel JM, al-Shabbout M, et al. Neuroendocrine response to 5-hydroxy-L-tryptophan in prepubertal children at high risk of major depressive disorder. Arch Gen Psychiatry. 1997 Dec. 54(12):1113-9. [Medline].
Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003 Mar. 58(3):249-65. [Medline].
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24. 57(2):203-9. [Medline].
Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006 Oct. 31(10):2281-8. [Medline].
McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006 May. 78(5):804-14. [Medline]. [Full Text].
Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry. 2002 Aug 1. 52(3):175-84. [Medline].
O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984 May. 93(2):158-71. [Medline].
Abramson, Lyn Y.; Metalsky, Gerald I.; Alloy, Lauren B. Hopelessness Depression: A Theory-Based Subtype of Depression. Psychol Rev. Apr 1989. Vol 96(2):358-372.
Hyde JS, Mezulis AH, Abramson LY. The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression. Psychol Rev. 2008 Apr. 115(2):291-313. [Medline].
Lewinsohn, P. M. A behavioral approach to depression. Friedman R.J. and Katz M.M. The psychology of depression: Contemporary theory and research. Washington, DC.: Winston-Wiley; 1974. 157-178.
Ferster, C. B. A functional analysis of depression. Am Psychol. 1973. 28, 857-870.
Martell, C. R., Addis, M. E., & Jacobson, N. S. Depression in context: Strategies for guided action. New York: Norton; 2001.
Frodl T, Reinhold E, Koutsouleris N, Donohoe G, Bondy B, Reiser M, et al. Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology. 2010 May. 35(6):1383-90. [Medline]. [Full Text].
Karg K, Burmeister M, Shedden K, Sen S. The Serotonin Transporter Promoter Variant (5-HTTLPR), Stress, and Depression Meta-analysis Revisited: Evidence of Genetic Moderation. Arch Gen Psychiatry. 2011 May. 68(5):444-54. [Medline].
De Bellis MD, Dahl RE, Perel JM, Birmaher B, al-Shabbout M, Williamson DE, et al. Nocturnal ACTH, cortisol, growth hormone, and prolactin secretion in prepubertal depression. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1130-8. [Medline].
Krishnan KR. Biological risk factors in late life depression. Biol Psychiatry. 2002 Aug 1. 52(3):185-92. [Medline].
Hammen C, Burge D, Adrian C. Timing of mother and child depression in a longitudinal study of children at risk. J Consult Clin Psychol. 1991 Apr. 59(2):341-5. [Medline].
Wickramaratne P, Gameroff MJ, Pilowsky DJ, Hughes CW, Garber J, Malloy E, et al. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry. 2011 Jun. 168(6):593-602. [Medline].
Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship?. J Affect Disord. 2004 Apr. 79(1-3):81-95. [Medline].
Klerman GL. The current age of youthful melancholia. Evidence for increase in depression among adolescents and young adults. Br J Psychiatry. 1988 Jan. 152:4-14. [Medline].
Gershon ES, Hamovit JH, Guroff JJ, Nurnberger JI. Birth-cohort changes in manic and depressive disorders in relatives of bipolar and schizoaffective patients. Arch Gen Psychiatry. 1987 Apr. 44(4):314-9. [Medline].
Current depression among adults---United States, 2006 and 2008. MMWR Morb Mortal Wkly Rep. 2010 Oct 1. 59(38):1229-35. [Medline].
Helgason T. Epidemiology of mental disorders in Iceland. A psychiatric and demographic investigation of 5395 Icelanders. Acta Psychiatr Scand. 1964. 40:SUPPL 173:1+. [Medline].
Jablensky A, Sartorius N, Gulbinat W, Ernberg G. Characteristics of depressive patients contacting psychiatric services in four cultures. A report from the who collaborative study on the assessment of depressive disorders. Acta Psychiatr Scand. 1981 Apr. 63(4):367-83. [Medline].
Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med. 2000 May. 30(3):505-14. [Medline].
Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, et al. Depression in Europe. Geographical distribution among older people. Br J Psychiatry. 1999 Apr. 174:312-21. [Medline].
Kashani JH, Sherman DD. Childhood depression: Epidemiology, etiological models, and treatment implications. Integr Psychiatry. 1988. 6:1-8.
Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. 1993 Feb. 102(1):133-44. [Medline].
Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL. Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Apr. 36(4):458-65. [Medline].
Hankin BL, Abramson LY, Moffitt TE, Silva PA, McGee R, Angell KE. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol. 1998 Feb. 107(1):128-40. [Medline].
Siegel JM, Aneshensel CS, Taub B. Adolescent depressed mood in a multiethnic sample. J Youth Adolesc. 1998. 27.
Tohen M, Khalsa HM, Salvatore P, et al. Two-year outcomes in first-episode psychotic depression The McLean-Harvard first-episode project. J Affect Disord. 2012 Jan. 136(1-2):1-8. [Medline].
Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP. J Am Acad Child Adolesc Psychiatry. 1998 Oct. 37(10 Suppl):63S-83S. [Medline].
Pine DS, Cohen E, Cohen P, Brook J. Adolescent depressive symptoms as predictors of adult depression: moodiness or mood disorder?. Am J Psychiatry. 1999 Jan. 156(1):133-5. [Medline].
Lespérance F, Frasure-Smith N. Depression and heart disease. Cleve Clin J Med. 2007 Feb. 74 Suppl 1:S63-6. [Medline].
Alexopoulos GS, Chester JG. Outcomes of geriatric depression. Clin Geriatr Med. 1992 May. 8(2):363-76. [Medline].
Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006 Mar. 63(3):435-40. [Medline].
Modrego PJ, Ferrández J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004 Aug. 61(8):1290-3. [Medline].
Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA. Association of depression with increased risk of dementia in patients with type 2 diabetes: the diabetes and aging study. Arch Gen Psychiatry. 2012 Apr. 69(4):410-7. [Medline].
Brooks M. Depression accelerates cognitive decline in type 2 diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/812762.. Accessed: October 22, 2013.
Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, et al. Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA Psychiatry. 2013 Oct 1. 70(10):1041-7. [Medline].
Li G, Wang LY, Shofer JB, et al. Temporal Relationship Between Depression and Dementia: Findings From a Large Community-Based 15-Year Follow-up Study. Arch Gen Psychiatry. 2011 Sep. 68(9):970-7. [Medline].
Gotlib I, Hammen C. (2002). Handbook of Depression. New York: Guilford Press; 2002:
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS). Available at http://www.cdc.gov/ncipc/wisqars. Accessed: March 19, 2010.
Conwell Y, Duberstein PR, Caine ED. Risk factors for suicide in later life. Biol Psychiatry. 2002 Aug 1. 52(3):193-204. [Medline].
Elovainio M, Shipley MJ, Ferrie JE, Gimeno D, Vahtera J, Marmot MG, et al. Obesity, unexplained weight loss and suicide: the original Whitehall study. J Affect Disord. 2009 Aug. 116(3):218-21. [Medline].
Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007 Jun 7. 356(23):2343-6. [Medline].
Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health care access in the United States: an ecological study. J Clin Psychiatry. 2006 Apr. 67(4):517-23. [Medline].
Sheikh RM, Weller EB, Weller RA. Prepubertal depression: diagnostic and therapeutic dilemmas. Curr Psychiatry Rep. 2006 Apr. 8(2):121-6. [Medline].
Spitz R. Anaclitic depression: An inquiry into the genesis of psychiatric conditions in early childhood. Psychoanalytic Study of the Child. 1946. Vol 2:313-342.
Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987 May. 150:662-73. [Medline].
SIGN. Postnatal Depression and Puerperal Psychosis: A National Clinical Guideline. Scottish Intercollegiate Guidelines Network. 2002. 32.
USPSTF. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009 Dec 1. 151(11):784-92. [Medline].
ACOG Committee Opinion No. 343: psychosocial risk factors: perinatal screening and intervention. Obstet Gynecol. 2006 Aug. 108(2):469-77. [Medline].
Peindl KS, Wisner KL, Hanusa BH. Identifying depression in the first postpartum year: guidelines for office-based screening and referral. J Affect Disord. 2004 May. 80(1):37-44. [Medline].
Wisner KL, Parry BL, Piontek CM. Clinical practice. Postpartum depression. N Engl J Med. 2002 Jul 18. 347(3):194-9. [Medline].
Beck CT. Postpartum depression: it isn't just the blues. Am J Nurs. 2006 May. 106(5):40-50; quiz 50-1. [Medline].
Imsiragic AS, Begic D, Martic-Biocina S. Acute stress and depression 3 days after vaginal delivery--observational, comparative study. Coll Antropol. 2009 Jun. 33(2):521-7. [Medline].
Scrandis DA, Sheikh TM, Niazi R, Tonelli LH, Postolache TT. Depression after delivery: risk factors, diagnostic and therapeutic considerations. ScientificWorldJournal. 2007 Oct 22. 7:1670-82. [Medline].
Spinelli MG. Antepartum and postpartum depression. J Gend Specif Med. 1998 Oct-Nov. 1(2):33-6. [Medline].
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr. 111(4):1001-20. [Medline].
Earls, Marian, MD. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics. 2010 Nov. 126(5):1032-9. [Medline].
Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 May 21. 136(10):765-76. [Medline].
Vogelzangs N, Beekman AT, Boelhouwer IG, et al. Metabolic depression: a chronic depressive subtype? findings from the InCHIANTI study of older persons. J Clin Psychiatry. 2011 May. 72(5):598-604. [Medline].
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002 Jul 17. 288(3):351-7. [Medline].
Luijendijk HJ, van den Berg JF, Hofman A, Tiemeier H, Stricker BH. ß-blockers and the risk of incident depression in the elderly. J Clin Psychopharmacol. 2011 Feb. 31(1):45-50. [Medline].
Portella MJ, de Diego-Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2011 Jul. 72(7):962-9. [Medline].
U.S. Preventive Services Task Force. Screening for Depression in Adults. U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/depression-in-adults-screening1. January 26, 2016; Accessed: January 27, 2016.
Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. Br J Gen Pract. 2007 Feb. 57(535):144-51. [Medline]. [Full Text].
Tutus A, Kibar M, Sofuoglu S, Basturk M, Gönül AS. A technetium-99m hexamethylpropylene amine oxime brain single-photon emission tomography study in adolescent patients with major depressive disorder. Eur J Nucl Med. 1998 Jun. 25(6):601-6. [Medline].
[Guideline] Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008 Nov 18. 149(10):725-33. [Medline]. [Full Text].
Chambless, D. L, Baker, M. J., Baucom, D. H., et al. Update on empirically validated therapies, II. Clin Psychol. 1998. 51, 3-16.
Task Force on Promotion and Dissemination of Psychological Procedures. Training in and dissemination of empirically validated psychological treatments. Clin Psychol. 1995. 48, 3-23.
Chambless, D. L., & Hollon, S. D. Defining empirically supported therapies. JCCP. 1998. 66, 7-18.
US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug safety communication – abnormal heart rhythms associated with high doses. Accessed August 24, 2011. [Full Text].
Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc. August, 2011. Available at [Full Text].
Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul. 73(7):953-9. [Medline].
Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun. 15(5):589-600. [Medline]. [Full Text].
Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi M. A randomized, double-blind, parallel group study comparing the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18-22, 2013; San Francisco, California. Poster NR9-02.
Jacobsen PL, Mahableshwarkar AR, Serenko M, Chen Y, Trivedi M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18-22, 2013; San Francisco, California. Poster NR9-06.
Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012 Jul. 27(4):215-23. [Medline].
Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012 Nov. 26(11):1408-16. [Medline].
Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012 Oct. 28(10):1717-24. [Medline].
Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5?mg and 5?mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013 Mar. 29(3):217-26. [Medline].
Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar. 16(2):313-21. [Medline].
Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. Am J Psychiatry. 2011 Jul. 168(7):689-701. [Medline].
Rexulti (brexpiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc. July 2015. Available at [Full Text].
Agency for Healthcare Research and Quality. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Accessed March 22, 2010. AHRQ: Agency for Healthcare Research and Quality. [Full Text].
Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, et al. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry. 2011 Oct. 72(10):1322-32. [Medline].
Fournier JC, DeRubeis RJ, Hollon ST, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. [Full Text].
Hopko DR, Lejuez CW, Ruggiero KJ, Eifert GH. Contemporary behavioral activation treatments for depression: procedures, principles, and progress. Clin Psychol Rev. 2003 Oct. 23(5):699-717. [Medline].
Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol. 1996 Apr. 64(2):295-304. [Medline].
Kanter JW, Manos RC, Bowe WM, Baruch DE, Busch AM, Rusch LC. What is behavioral activation? A review of the empirical literature. Clin Psychol Rev. 2010 Aug. 30(6):608-20. [Medline].
Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif. 2001 Apr. 25(2):255-86. [Medline].
Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006 Aug. 74(4):658-70. [Medline].
McCauley, E., Schloredt, K., Gudmundsen, G., et al. Expanding behavioral activation to depressed adolescents: Lessons learned in treatment development. Cogn and Behav Pract. 2011. 18, 371-383.
Meeks S, Looney SW, Van Haitsma K, Teri L. BE-ACTIV: a staff-assisted behavioral intervention for depression in nursing homes. Gerontologist. 2008 Feb. 48(1):105-14. [Medline].
Sood, J. R., Cisek, E., Zimmerman, J., et al. Treatment of depressive symptoms during short-term rehabilitation: an attempted replication of the DOUR project. Rehabil Psychol. 2003. 48, 44-49.
Quijano, L. M., Stanley, M. A., Peterson, N. J., et al. Healthy Ideas: a depression intervention delivered by community-based case managers serving older adults. J Appl Gerontol. 2007. 26:139-156.
Young JE, Weinberger AD, Beck, AT. Cognitive therapy for depression. Barlow D.H. Clinical handbook of psychological disorders: A step-by-step treatment manual. Third Edition. New York: Guilford Press; 2001. 264-308.
Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press; 1979.
Areán PA, Cook BL. Psychotherapy and combined psychotherapy/pharmacotherapy for late life depression. Biol Psychiatry. 2002 Aug 1. 52(3):293-303. [Medline].
Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006 Sep. 163(9):1493-501. [Medline].
Klerman, G. L., Weissman, M. M., Rounsaville, B. J., et al. Interpersonal Psychotherapy of Depression. New York: Basic Books; 1984.
Gillies, L. A. Interpersonal psychotherapy for depression and other disorders. Barlow D.H. Clinical Handbook of Psychological Disoders: A Step-by-Step Treatment Manual. 3rd ed. New York: The Guilford Press; 2001.
Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: a one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1145-55. [Medline].
Reynolds CF 3rd, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999 Jan 6. 281(1):39-45. [Medline].
Kabat-Zinn, J. Full Catastrophe Living: The program of the Stress Reduction Clinic at the University of Massachusetts Medical Center. New York: Delta; 1990.
Segal, Z. V., Teasdale, J. D., & Williams, J. M. G. Mindfulness-based cognitive therapy: Theoretical rationale and empirical status. Hayes, S.C., Follette, V.M. and Linehan, M.M. Mindfulness and Acceptance: Expanding the Cognitive-Behavioral Tradition. New York: Guilford Press; 2011.
Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. Mindfulness based cognitive therapy for depression: A new approach to preventing relapse. New York: Guilford Press; 2002.
Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000 Aug. 68(4):615-23. [Medline].
Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004 Feb. 72(1):31-40. [Medline].
Kuyken W, Warren FC, Taylor RS, Whalley B, Crane C, Bondolfi G, et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry. 2016 Apr 27. [Medline].
Nezu, A. M., Nezu, C. M., & D’Zurilla, T. J. Solving life’s problems: A 5-step guide to enhanced well-being. New York: Springer; 2007.
Nezu AM, Ronan GF. Life stress, current problems, problem solving, and depressive symptoms: an integrative model. J Consult Clin Psychol. 1985 Oct. 53(5):693-7. [Medline].
Nezu, A. M., Nezu, C. M., Saraydarian, L., et al. Social problem solving as a moderator variable between negative life stress and depressive symptoms. Cognitive Ther Res. 1986. 10:489-498.
Nezu, A. M. Problem solving and behavior therapy revisited. Behav Ther. 2004. 35:1-33.
D’Zurilla, T. J. & Nezu, A. M. Problem-solving therapy: A positive approach to clinical intervention. 3rd ed. New York: Springer; 2007.
D’Zurilla, T. J., Nezu, A. M., & Maydeu-Olivares, A. Social problem solving: Theory and assessment. Chang, E.C., D’Zurilla, T.J., & Sanna, L.J. Social problem solving: Theory, research, and training. Washington, DC: American Psychological Association; 2004. 11-27.
Nezu, A. M., Nezu, C. M., & Lombardo, E. Problem-solving therapy. O’Donohue, W., Fisher, J. E. & Hayes, S. C.,. Cognitive behavior therapy: Applying empirically supported techniques in your practice. Hoboken, NJ: John Wiley & Sons; 2003. 301-307.
Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol. 1986 Apr. 54(2):196-202. [Medline].
Nezu AM, Perri MG. Social problem-solving therapy for unipolar depression: an initial dismantling investigation. J Consult Clin Psychol. 1989 Jun. 57(3):408-13. [Medline].
Arean PA, Perri MG, Nezu AM, Schein RL, Christopher F, Joseph TX. Comparative effectiveness of social problem-solving therapy and reminiscence therapy as treatments for depression in older adults. J Consult Clin Psychol. 1993 Dec. 61(6):1003-10. [Medline].
Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ. 1995 Feb 18. 310(6977):441-5. [Medline]. [Full Text].
Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. BMJ. 2000 Dec 9. 321(7274):1450-4. [Medline]. [Full Text].
Lam RW, Levitt AJ, Levitan RD, Michalak EE, Morehouse R, Ramasubbu R, et al. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Nov 18. 1-9. [Medline].
Lieverse R, Van Someren EJ, Nielen MM, Uitdehaag BM, Smit JH, Hoogendijk WJ. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2011 Jan. 68(1):61-70. [Medline].
Wirz-Justice A, Bader A, Frisch U, Stieglitz RD, Alder J, Bitzer J, et al. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. J Clin Psychiatry. 2011 Jul. 72(7):986-93. [Medline].
Cassels C. FDA Clears TMS Device for Resistant Depression. Medscape Medical News. Jan 9 2013. [Full Text].
Krogh J, Nordentoft M, Sterne JA, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2011 Apr. 72(4):529-38. [Medline].
Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011 May. 168(5):502-10. [Medline].
Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A, et al. The Sertraline vs Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial, Randomized, Controlled Trial. JAMA Psychiatry. 2013 Feb 6. 1-9. [Medline].
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov. 163(11):1905-17. [Medline].
Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety. 2011 Jul. 28(7):521-4. [Medline].
Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Jun. 68(6):843-53. [Medline].
Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008 Apr. 28(2):156-65. [Medline].
Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009 Apr. 14(4):197-206. [Medline].
Lowry F. Vagus nerve stimulation effective in resistant depression. Medscape Medical News. May 16, 2013. [Full Text].
Conway CR, Chibnall JT, Gebara MA, Price JL, Snyder AZ, Mintun MA, et al. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression. Brain Stimul. 2013 Feb 13. [Medline].
Cassels C. TMS for resistant depression: long-term results are in. Medscape Medical News. May 24, 2013. [Full Text].
March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct. 64(10):1132-43. [Medline].
Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, et al. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jun. 46(6):667-86. [Medline].
Brent DA. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depress Anxiety. 2009. 26(10):871-4. [Medline].
Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Jun. 36(6):725-36. [Medline].
Rey-Sánchez F, Gutiérrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 1997 Oct. 36(10):1443-7. [Medline].
Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008 Jul. 193(1):10-7. [Medline].
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997 Nov. 54(11):1031-7. [Medline].
March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct. 64(10):1132-43. [Medline].
Cassels C. FDA Suicide Warnings Change Antidepressant Prescribing Patterns, but Physicians Ignore Monitoring Recommendations. Medscape Today. Available at http://www.medscape.com/viewarticle/715952. Accessed: March 22, 2010.
Cassels C. FDA Suicide Warnings About Antidepressants Cut Rates of Depression Diagnosis and Treatment. Medscape Today. Available at http://www.medscape.com/viewarticle/704235. Accessed: March 22, 2010.
Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011 May. 72(5):580-6. [Medline].
Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001 Oct-Nov. 10(6):525-30. [Medline].
Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. 2003 May 10. 326(7397):1008. [Medline]. [Full Text].
Olfson M, Marcus SC, Druss B, Pincus HA. National trends in the use of outpatient psychotherapy. Am J Psychiatry. 2002 Nov. 159(11):1914-20. [Medline].
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004 Aug 18. 292(7):807-20. [Medline].
Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006 Jan. 163(1):41-7. [Medline].
Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010 Oct. 67(10):1012-24. [Medline].
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006 Feb 9. 354(6):579-87. [Medline]. [Full Text].
Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry. 2012 Feb. 169(2):134-40. [Medline].
FDA drug safety communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. US Food and Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed: December 14, 2011.
Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006 Feb. 160(2):173-6. [Medline].
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009 Sep. 114(3):703-13. [Medline].
Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004 Jul. 161(7):1290-2. [Medline].
Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004 Jun. 161(6):1066-78. [Medline].
Andreescu C, Lenze EJ, Mulsant BH, Wetherell JL, Begley AE, Mazumdar S, et al. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depress Anxiety. 2009. 26(3):266-72. [Medline]. [Full Text].
Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011 Jul. 168(7):681-8. [Medline].
Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004 Feb 9. 164(3):327-32. [Medline].
King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994. 31(4):271-9. [Medline].
Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993 Mar. 8(3):186-212. [Medline].
Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010 Aug. 167(8):934-41. [Medline].
Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 Sep. 166(9):980-91. [Medline].
Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006 Nov 27. 166(21):2314-21. [Medline].
Kroll L, Harrington R, Jayson D, Fraser J, Gowers S. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1156-61. [Medline].
A Message From APA President Dilip Jeste, M.D., on DSM-5. Available at http://www.psychnews.org/files/DSM-message.pdf. Accessed: December 1, 2012.
Anderson P. Stimulation device shows 'immediate' impact on depression. Medscape Medical News. July 31, 2014. [Full Text].
Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 Mar. 74(3):242-8. [Medline].
Bender K. Cognitive therapy, meds equal in curbing depression relapse. Medscape Medical News. November 20, 2013. [Full Text].
Brauser D. Depression Causally Linked to Heart Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/820313. Accessed: February 12, 2014.
Brunner EJ, Shipley MJ, Britton AR, Stansfeld SA, Heuschmann PU, Rudd AG, et al. Depressive disorder, coronary heart disease, and stroke: dose-response and reverse causation effects in the Whitehall II cohort study. Eur J Prev Cardiol. 2014 Feb 3. [Medline].
Cassels C. FDA Approves New SNRI for Major Depression. Medscape Medical News. Available at http://www.medscape.com/viewarticle/808481.. Accessed: August 6, 2013.
Cassels C. FDA Approves Vortioxetine for Major Depression. Medscape Medical News. Available at http://www.medscape.com/viewarticle/811892. Accessed: October 8, 2013.
Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database Syst Rev. 2013 Feb 28. 2:CD001134. [Medline].
Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997 Mar. 170:205-28. [Medline].
Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, et al. Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications. Clin Infect Dis. 2013 Feb 13. [Medline].
Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry. 2013 Nov 1. 70(11):1152-60. [Medline].
Rohan ML, Yamamoto RT, Ravichandran CT, et al. Rapid mood-elevating effects of low field magnetic stimulation in depression. Biol Psychiatry. 2014 Aug 1. 76(3):186-93. [Medline].
Steingard RJ, Renshaw PF, Yurgelun-Todd D, Appelmans KE, Lyoo IK, Shorrock KL, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry. 1996 Mar. 35(3):307-11. [Medline].
|level of support||Therapy|
|Efficacious and specific||Interpersonal psychotherapy (IPT)|
|Cognitive behavior therapy (CBT)|
|Problem-solving therapy (PST)|
|Behavioral activation (BA)/contingency management|
|Possibly efficacious||Dynamic psychotherapy|
|Cognitive behavioral analysis system for psychotherapy (CBASP)|
|Emotion-focused therapy (EFT)|
|level of support||Therapy|
|Efficacious and specific||Prior CBT to prevent relapse|
|Efficacious||Mindfulness-based cognitive therapy (MBCT) to prevent relapse/recurrence|
|Possibly efficacious||Prior dynamic psychotherapy to prevent recurrence|
|Maintenance IPT to prevent recurrence|
|Continuation cognitive therapy (CT) to prevent relapse/recurrence|
|Maintenance CBASP to prevent recurrence|
|EFT to prevent relapse|
|Treatment||Response Rate (%)|
|Week 12||Week 18||Week 36|
|Cognitive-behavioral therapy (CBT)||48||65||81|
|Fluoxetine plus CBT||73||85||86|